Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Immunology›Phagocytosis
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Phagocytosis

Immunology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (phagocytes).

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (808 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (phagocytes).

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Phagocytoses.

Where it fits in the MeSH classification

Broader topics
Endocytosis; Blood Physiological Phenomena; Immunity, Innate; Immune System Phenomena
Narrower topics
Cytophagocytosis; Opsonization
See also
Macrophages

Related concepts

  • Phagocytes

Research landscape

PubMed indexes 56,479 records tagged with the MeSH heading “Phagocytosis” (counts retrieved 2026-10-29). 6,855 of them (12.1%) were published from 2020 onward, and the busiest period so far is through 1999 with 30,506 records.

Reviews account for 5,382 records (9.5%) and meta-analyses for 11. Randomized controlled trials number 273 (0.5%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 30,506 records; 2000-2009: 8,770 records; 2010-2019: 10,348 records; 2020 onward: 6,855 records30,506through 19998,7702000-200910,3482010-20196,8552020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199930,506
2000-20098,770
2010-201910,348
2020 onward6,855
Share of records by publication typeReviews: 9.5 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 0.5 percentReviews9.5% (5,382)Meta-analyses0.0% (11)Randomized controlled trials0.5% (273)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 56,479 PubMed records
TypeRecordsShare
Reviews5,3829.5%
Meta-analyses110.0%
Randomized controlled trials2730.5%

Method: PubMed query "Phagocytosis"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in immunology

Immune responses are studied in model organisms, in cells from donors and in patients, and the same pathway can behave differently across these settings. Mouse immune systems differ from human ones in important ways, and blood measurements may not reflect what happens in tissues. Clinical conclusions about immune-mediated disease or immunotherapy come mainly from controlled trials and long-term cohorts. Check the species and tissue studied, whether markers were linked to outcomes patients notice, and the follow-up time.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity
Zhou X, Zhu D, Wu D, Li G, Liang H, Zhang W, et al.
2025Research article
Design not recorded in structured metadata
29cc by
PMID 40199328 · DOI · PMC12047514
Early life high fructose impairs microglial phagocytosis and neurodevelopment
Wang Z, Lipshutz A, Martínez de la Torre C, Trzeciak AJ, Liu ZL, Miranda IC, et al.
2025Research article
Design not recorded in structured metadata
26cc by
PMID 40500435 · DOI · PMC7617807
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
Russell SN, Demetriou C, Valenzano G, Evans A, Go S, Stanly T, et al.
2025Research article
Design not recorded in structured metadata
24cc by
PMID 39788719 · DOI · PMC12013568
Piezo1 Upregulation in Monocyte-Derived Macrophages Impairs Post-Myocardial Infarction Cardiac Repair via Defective Efferocytosis and Enhanced Ferroptosis
Peng L, Xia Y, Zhao H, Guo Y, Xu X, Han X, et al.
2026Research article
Design not recorded in structured metadata
13cc by
PMID 41214880 · DOI · PMC12850066

Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity [1]

Research article Zhou X, Zhu D, Wu D, Li G, Liang H, Zhang W, et al. · · 2025 · cited 29 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Macrophages eliminate apoptotic cells produced daily in the body through efferocytosis.
Closing excerpt
Our study explores the therapeutic potential of CAR-eM efferocytosis for IDD treatment.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (147 words)

Macrophages eliminate apoptotic cells produced daily in the body through efferocytosis. Restricted clearance can cause inflammation-related diseases. In intervertebral discs (IVDs), apoptotic nucleus pulposus cells (NPCs) are difficult to effectively remove, and their accumulation can cause changes in the inflammatory microenvironment, disrupt IVD homeostasis, and lead to IVD degeneration (IDD). Here, we present chimeric antigen receptor-M-like engineered macrophages (CAR-eMs) with enhanced efferocytosis capacity for IDD treatment. Macrophages undergo phenotypic transformation and a reduction in phagocytic ability after phagocyting apoptotic NPCs, but their efferocytosis capacity recovers with upregulated brain-specific angiogenesis inhibitor 1 (BAI1) expression. We develop a CAR-eM system with enhanced BAI1 expression and an IVD circular microneedle (MN) delivery system that utilizes arrays of MNs to deliver CAR-eMs into the deep IVD layers, thereby clearing apoptotic NPCs, ameliorating the inflammatory microenvironment, and repairing damaged IVDs. Our study explores the therapeutic potential of CAR-eM efferocytosis for IDD treatment.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40199328 · DOI · PMC12047514

Early life high fructose impairs microglial phagocytosis and neurodevelopment [2]

Research article Wang Z, Lipshutz A, Martínez de la Torre C, Trzeciak AJ, Liu ZL, Miranda IC, et al. · · 2025 · cited 26 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Despite the success of fructose as a low-cost food additive, epidemiological evidence suggests that high fructose consumption during pregnancy or adolescence is associated with disrupted neurodevelopment1-3.
Closing excerpt
Our findings provide a mechanistic explanation for the epidemiological observation that high-fructose exposure during early life is associated with increased prevalence of adolescent anxiety disorders.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (225 words)

Despite the success of fructose as a low-cost food additive, epidemiological evidence suggests that high fructose consumption during pregnancy or adolescence is associated with disrupted neurodevelopment1-3. An essential step in appropriate mammalian neurodevelopment is the phagocytic elimination of newly formed neurons by microglia, the resident professional phagocyte of the central nervous system4. Whether high fructose consumption in early life affects microglial phagocytosis and whether this directly affects neurodevelopment remains unknown. Here we show that offspring born to female mice fed a high-fructose diet and neonates exposed to high fructose exhibit decreased phagocytic activity in vivo. Notably, deletion of the high-affinity fructose transporter GLUT5 (also known as SLC2A5) in neonatal microglia completely reversed microglia phagocytic dysfunction, suggesting that high fructose directly affects neonatal development by suppressing microglial phagocytosis. Mechanistically, we found that high-fructose treatment of mouse and human microglia suppresses phagocytosis capacity, which is rescued in GLUT5-deficient microglia. Additionally, we found that high fructose drives significant GLUT5-dependent fructose uptake and catabolism to fructose 6-phosphate, rewiring microglial metabolism towards a hypo-phagocytic state in part by enforcing mitochondrial localization of the enzyme hexokinase 2. Mice exposed to high fructose as neonates develop anxiety-like behaviour as adolescents-an effect that is rescued in GLUT5-deficient mice. Our findings provide a mechanistic explanation for the epidemiological observation that high-fructose exposure during early life is associated with increased prevalence of adolescent anxiety disorders.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40500435 · DOI · PMC7617807

Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control [3]

Research article Russell SN, Demetriou C, Valenzano G, Evans A, Go S, Stanly T, et al. · · 2025 · cited 24 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundThe immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical studies have implicated macrophage-mediated immune tolerance.
Closing excerpt
ConclusionsOur data supports a new immunotherapeutic approach and a translational rationale to improve survival in PDAC.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (238 words)

BackgroundThe immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical studies have implicated macrophage-mediated immune tolerance. Hence, pathways that regulate macrophage phenotype are of strategic interest, with reprogramming strategies focusing on inhibitors of phosphoinositide 3-kinase-gamma (PI3Kγ) due to restricted immune cell expression. Inhibition of PI3Kγ alone is ineffective in PDAC, despite increased infiltration of CD8+ T cells.ObjectiveWe hypothesised that the immune stimulatory effects of radiation, and its ability to boost tumour antigen availability could synergise with PI3Kγ inhibition to augment antitumour immunity.DesignWe used orthoptic and genetically engineered mouse models of pancreatic cancer (LSL-KrasG12D/+;Trp53R172H/+;Pdx1-Cre). Stereotactic radiotherapy was delivered using contrast CT imaging, and PI3Kγ inhibitors by oral administration. Changes in the tumour microenvironment were quantified by flow cytometry, multiplex immunohistochemistry and RNA sequencing. Tumour-educated macrophages were used to investigate efferocytosis, antigen presentation and CD8+ T cell activation. Single-cell RNA sequencing data and fresh tumour samples with autologous macrophages to validate our findings.ResultsTumour-associated macrophages that employ efferocytosis to eradicate apoptotic cells can be redirected to present tumour antigens, stimulate CD8+ T cell responses and increase local tumour control. Specifically, we demonstrate how PI3Kγ signalling restricts inflammatory macrophages and that inhibition supports MERTK-dependent efferocytosis. We further find that the combination of PI3Kγ inhibition with targeted radiotherapy stimulates inflammatory macrophages to invoke a pathogen-induced like efferocytosis that switches from immune tolerant to antigen presenting.ConclusionsOur data supports a new immunotherapeutic approach and a translational rationale to improve survival in PDAC.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39788719 · DOI · PMC12013568

Piezo1 Upregulation in Monocyte-Derived Macrophages Impairs Post-Myocardial Infarction Cardiac Repair via Defective Efferocytosis and Enhanced Ferroptosis [4]

Research article Peng L, Xia Y, Zhao H, Guo Y, Xu X, Han X, et al. · · 2026 · cited 13 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The regulation of macrophage function, particularly that of monocyte-derived macrophages (MoMs), by mechanical forces during myocardial infarction (MI) remains poorly understood.
Closing excerpt
These data establish an ischemic heart-bone marrow functional network and provide a novel therapeutic strategy in which MoM Piezo1 is targeted for post-MI heart repair.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (198 words)

The regulation of macrophage function, particularly that of monocyte-derived macrophages (MoMs), by mechanical forces during myocardial infarction (MI) remains poorly understood. Consistently upregulated Piezo1 expression in cardiac macrophages and MoMs post-MI is found. Elevated Piezo1 expression in MoMs directly contributes to increased Piezo1 levels in cardiac macrophages. Myeloid cell-specific Piezo1-deficient mice (Piezo1Lyz2) exhibit significant improvements in ventricular function/remodeling after MI, accompanied by decreased apoptotic cardiomyocytes and decreased inflammation, increased numbers of macrophages, and increased border zone efferocytosis. In vitro, Piezo1 activation by Yoda1 increased oxygen-glucose deprivation (OGD)-induced ferroptosis and impaired MoM efferocytosis. Conversely, Piezo1 deficiency in MoMs decreases ferroptosis and increases efferocytosis. SLC7A11 is shown to mediate Piezo1-induced defective efferocytosis in MoMs. Piezo1 activation aggravated OGD-induced macrophage ferroptosis via Ca2+ influx followed by SLC15A3 upregulation. Piezo1 upregulated SLC7A11 in macrophages via a Ca2+/ATF4-dependent pathway. MoM-specific SLC7A11 knockdown significantly increases efferocytosis, reduces cardiomyocyte apoptosis and inflammation, and ameliorates post-MI left ventricular remodeling and function. In conclusion, early Piezo1 activation in MoMs is identified during MI, which governs the fate and function of recruited macrophages. These data establish an ischemic heart-bone marrow functional network and provide a novel therapeutic strategy in which MoM Piezo1 is targeted for post-MI heart repair.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41214880 · DOI · PMC12850066

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Microglia emerge as central players in brain disease [5]
    Salter MW, Stevens B · Nat Med · 2017 · cited 1,488 times (Europe PMC)
  • Research article Efferocytosis in health and disease [6]
    Doran AC, Yurdagul A, Tabas I · Nat Rev Immunol · 2020 · cited 904 times (Europe PMC)
  • Research article Apoptosis and Clearance of Apoptotic Cells [7]
    Nagata S · Annu Rev Immunol · 2018 · cited 874 times (Europe PMC)
  • Research article Phagocytosis of apoptotic cells in homeostasis [8]
    Arandjelovic S, Ravichandran KS · Nat Immunol · 2015 · cited 775 times (Europe PMC)
  • Research article Microglial phagocytosis of live neurons [9]
    Brown GC, Neher JJ · Nat Rev Neurosci · 2014 · cited 730 times (Europe PMC)
  • Research article The clearance of dead cells by efferocytosis [10]
    Boada-Romero E, Martinez J, Heckmann BL, Green DR · Nat Rev Mol Cell Biol · 2020 · cited 729 times (Europe PMC)

References

  1. Zhou X, Zhu D, Wu D, Li G, Liang H, Zhang W, et al.. Microneedle delivery of CAR-M-like engineered macrophages alleviates intervertebral disc degeneration through enhanced efferocytosis capacity. . 2025. PMID 40199328 · DOI · PMC12047514
  2. Wang Z, Lipshutz A, Martínez de la Torre C, Trzeciak AJ, Liu ZL, Miranda IC, et al.. Early life high fructose impairs microglial phagocytosis and neurodevelopment. . 2025. PMID 40500435 · DOI · PMC7617807
  3. Russell SN, Demetriou C, Valenzano G, Evans A, Go S, Stanly T, et al.. Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control. . 2025. PMID 39788719 · DOI · PMC12013568
  4. Peng L, Xia Y, Zhao H, Guo Y, Xu X, Han X, et al.. Piezo1 Upregulation in Monocyte-Derived Macrophages Impairs Post-Myocardial Infarction Cardiac Repair via Defective Efferocytosis and Enhanced Ferroptosis. . 2026. PMID 41214880 · DOI · PMC12850066
  5. Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017. PMID 28886007 · DOI
  6. Doran AC, Yurdagul A, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020. PMID 31822793 · DOI · PMC7667664
  7. Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 2018. PMID 29400998 · DOI
  8. Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015. PMID 26287597 · DOI · PMC4826466
  9. Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci. 2014. PMID 24646669 · DOI
  10. Boada-Romero E, Martinez J, Heckmann BL, Green DR. The clearance of dead cells by efferocytosis. Nat Rev Mol Cell Biol. 2020. PMID 32251387 · DOI · PMC7392086

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Disease ResistanceImmunology
  • Trained ImmunityImmunology
  • Acute Generalized Exanthematous PustulosisImmunology
  • Adaptive ImmunityImmunology
  • Addison DiseaseImmunology
  • AgammaglobulinemiaImmunology

All 90 articles in Immunology →

At a glance

56,479
PubMed records on this heading
12%
published since 2020
5,382
review articles
273
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Disease ResistanceImmunology
  • Trained ImmunityImmunology
  • Acute Generalized Exanthematous PustulosisImmunology
  • Adaptive ImmunityImmunology
  • Addison DiseaseImmunology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support